Institut National De La Sante Et De La Recherche Medicale

Université Paris Descartes

University of California

Merck Serono S. a.

Université Paris Diderot-Paris 7

Assistance Publique - Hopitaux De Paris (Aphp)

Duke University

Assistance Publique-Hopitaux De Paris

Université Pierre Et Marie Curie

Txcell

Centre National De La Recherche Scientifique

Sorbonne Université

Université Paul Sabatier (Toulouse III)

Inserm (Institut National De La Sante Et De La Recherche Medicale)

Université Paris 7—Denis Diderot

Alain Tedgui

Ziad Mallat

Joseph L Witztum

Sotirios Tsimikas

Yolande Chvatchko

Hafid Ait-Oufella

Thomas F Tedder

Thomas Tedder

Hervé Groux

Pierre-Emmanuel Rautou

Valérie Brun

Jean-Sebastien Silvestre

Chantal Boulanger

Pierre Louis Tharaux

Nicolas Danchin

Louis Casteilla

Valérie Planat-Benard

Luc Penicaud

Jean-Sébastien Silvestre

Tabassome Simon

Joëlle Benessiano

Jean-Marie Freyssinet

Soraya Taleb

Philippe Gabriel Steg

Fatima-Soraya Taleb

Branka Horvat

Xavier Loyer

Valerie Planat-Benard

Bernard Levy

Gérard London

Hafid Ait-oufella

The present invention relates to the prevention or treatment of atherosclerosis, in particular to a B cell depleting agent for the prevention or treatment of atherosclerosis.

B cell depleting agent for the treatment of atherosclerosis

The present invention relates to methods and pharmaceutical compositions for the treatment of obesity. In particular, the present invention relates to a method of treating obesity in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an indoleamine 2-3 dioxygenase (IDO) inhibitor.

Methods and pharmaceutical compositions for the treatment of obesity

The present invention relates to a method for predicting the survival time of a patient suffering from myocardial infarction or the recurrence of a myocardial infarction. The method comprises the steps of i) determining the expression level of BAFF in a sample from the patient, ii) comparing the expression level with a predetermined reference value and iii) providing a good prognosis of the survival time or a low risk of the recurrence of a myocardial infarction when the expression level is lower than the predetermined reference value and a poor prognosis of the survival time or a high risk of the recurrence of a myocardial infarction when the expression level is higher than the predetermined reference value.

Method of predicting survival time in myocardial infarction patients by measuring BAFF levels

The invention relates to the use of an inhibitor of IL-18 in the preparation of a medicament for treatment and/or prevention of peripheral vascular diseases. The invention further relates to the use of an IL-18 inhibitor for prevention of limb amputation.

Use of IL-18BP for treatment of peripheral vascular diseases

The present invention relates to a compound which is an antagonist of IL-1 beta or an inhibitor of IL-1 beta expression for use in the treatment or the prevention of aneurysm. In another embodiment, the invention relates to a pharmaceutical composition for use in the treatment or the prevention of aneurysm comprising an antagonist of IL-1 beta or an inhibitor of IL-1 beta expression.

Method for use in the treatment of aneurysm

Method of treating peripheral vascular diseases using IL-18 inhibitors

The present invention relates to the treatment of nonalcoholic steatohepatitis (NASH), in particular to a compound that inhibits miR-21 expression for use in the treatment of nonalcoholic steatohepatitis.

Methods for the treatment of nonalcoholic steatohepatitis

The present invention relates to methods for producing a non human animal model for aortic aneurysm which could provide insight into the diagnosis and treatment of disease. Furthermore, the present invention relates to methods and compositions for the treatment or the prevention of aneurysm in a subject in need thereof.

Methods for producing a non human model for aortic aneurysm

The present invention related to a method of identifying a subject having or at risk of having or developing a cardiovascular disease and/or a cardiovascular event, comprising: &#x2014;measuring, in a sample obtained from said subject, at least two cardiovascular risk factors: a) sPLA2 type HA mass and b) oxidized phospholipids on apolipoprotein B-IOO particles (OxPL/apoB), &#x2014;combining said measurements, the combined value of sPLA2 type HA mass and OxPL/apoB being indicative of having or a risk of having or developing a cardiovascular disease and/or cardiovascular event.

Combination of sPLA2 type IIA mass and OXPL/APOB cardiovascular risk factors for the diagnosis/prognosis of a cardiovascular disease/event

The use of a combination of sPLA2 activity and OxPL/apoB cardiovascular risk factors for the diagnosis/prognosis of a cardiovascular disease/event or for the monitoring of a cardiovascular disease.

Combination of sPLA2 activity and oxPL/apoB cardiovascular risk factors for the diagnosis/prognosis of a cardiovascular disease/event

The present invention concern a composition or a patch adapted for the prophylactic or therapeutic treatment by continuous subcutaneous administration of a subject suffering from atherosclerosis, comprising an effective amount of at least one epitope derived from a protein present in the atherosclerotic plaque, whereby administration of said at least one epitope to said subject induces a specific regulatory immune response, preferably a Treg response.

Composition for the treatment of atherosclerosis

A method for determining an increased risk of mortality or of a cardiac and/or vascular event in a patient, includes:&#x2014;determining the sPLA2 activity of the patient as a first risk marker&#x2014;determining at least the value of a second risk marker chosen among CRP level, IgM IC of apo B 100 level or IgM MDA-LDL level&#x2014;determining the ratio (odds ratio) between the value of the sPLA2 activity and the value of the second risk marker and comparing it to a predetermined odds ratio, the odds ratio compared to the predetermined odds ratio being indicative of an increased risk of mortality or of a cardiac and/or vascular event. A new micro method adaptation for automated fluorimetric measurement of serum secretory phospholipase A2 is also disclosed.

[object Object]

A method of identifying a subject having or at risk of having or developing a cardiovascular disease and/or a cardiovascular event, includes:

Combination of sPLA2 activity and OxPL/apoB cardiovascular risk factors for the diagnosis/prognosis of a cardiovascular disease/event

The present invention relates to a method of treating or preventing atherosclerosis comprising administering to a mammal in need of such a treatment a) an antigen which has been used to activate in vitro a Tri cell population originating from said mammal, and b) the TO cell population activated by said antigen, said TO cell population being obtained from a CD4+ T lymphocyte population of said mammal.

Tr1 cells for use in atherosclerosis

Growing community of inventors

Paris, France

Alain Tedgui